FDA sideswipes Neoleukin with clinical hold on lead immunotherapy candidate, sends shares plummeting

FDA sideswipes Neoleukin with clinical hold on lead immunotherapy candidate, sends shares plummeting

Submitted by admin on January 8, 2021 - 9:34am
Source: 
Endpoints
News Tags: 
Neoleukin
NL-201
FDA
natural killer cell therapy
oncology
clinical trials
Headline: 
FDA sideswipes Neoleukin with clinical hold on lead immunotherapy candidate, sends shares plummeting
snippet: 

The FDA has placed a clinical hold on Neoleukin’s IND application for NL-201, a de novo cytokine receptor agonist for IL-2 and IL-15, which it hoped to test in expanding CD8 T cells and natural killer cells for use in oncologic therapeutic areas, the company said Friday.

Do Not Allow Advertisers to Use My Personal information